Main Uses of Vestinorm

Vestinorm is primarily used to manage symptoms associated with vestibular disorders, which affect balance and spatial orientation. The active component is intended to address conditions that originate in the inner ear or the vestibular system.

Meniere's Disease

One of the primary indications for Vestinorm is Meniere's disease. This condition is characterized by a specific triad of symptoms that impact a person's quality of life:

• Vertigo: Recurrent episodes of a spinning sensation, often accompanied by nausea or vomiting.
• Tinnitus: The perception of ringing, buzzing, or other noises in the ears without an external source.
• Hearing Loss: Progressive or fluctuating difficulty in hearing, often localized to one ear.

Vestibular Vertigo

Vestinorm is also utilized for the symptomatic treatment of vestibular vertigo. This refers to a sensation of movement or dizziness caused by dysfunction in the peripheral vestibular system. It helps in reducing the frequency and intensity of these dizzy spells, allowing for better daily functioning.

Therapeutic Benefits

The pharmacological action of Vestinorm is centered on improving the physiological environment of the inner ear. By interacting with specific receptors, it facilitates several beneficial processes:

• Microcirculation Improvement: It helps optimize blood flow within the capillaries of the inner ear, which is essential for the health of sensory cells.
• Endolymphatic Pressure Regulation: It assists in normalizing the pressure of the fluid (endolymph) inside the labyrinth of the ear, which is often elevated in balance disorders.
• Compensation Support: It may aid the brain's natural ability to adapt to vestibular imbalances, helping the nervous system recover more effectively after an episode of vertigo.

Regulatory References

1. European Commission's Union Register of medicinal products

The eligibility profile for Вестинорм (Betahistine) is strictly defined by regulatory authorities, outlining populations for whom use is prohibited, restricted, or not established.

Eligibility Scope

Classification	Population or Condition
Contraindicated (Must not use)	Patients with Phaeochromocytoma or known Hypersensitivity to the drug or its components. Some labels also contraindicate active or historical Peptic Ulcer [1.4, 1.6].
Use with Caution	Patients with Bronchial Asthma or conditions like allergic rhinitis or urticaria [1.5].
Not Recommended	Children and Adolescents (below 18 years) due to insufficient safety and efficacy data [1.1, 1.4].

Reproductive and Organ Status

Status	Regulatory Statement
Pregnancy	Use is preferable to be avoided as there are no adequate data on its use in pregnant women [1.4].
Lactation	Not known if the drug is excreted in human milk; the decision must weigh the benefit to the mother against the potential risk to the child [1.4].
Hepatic/Renal Impairment	No dose adjustment appears necessary based on post-marketing experience, though specific clinical trial data are limited in these groups [1.4].

This structure reflects how official regulatory documents strictly define who can and cannot use the medicine, establishing absolute exclusions and populations requiring conditional use or for whom data is formally lacking.

The official regulatory profile for betahistine dihydrochloride focuses on documented interaction patterns that modify its metabolism and its physiological action as a histamine analogue. No drug combinations are formally classified as strictly contraindicated due to interaction risk in the primary regulatory sources, and no mandatory timing separation rules are specified.

Interaction Category	Interacting Substances	Official Regulatory Outcome
Metabolic (PK) Interaction	Monoamine Oxidase Inhibitors (MAOIs), including MAO-B selective inhibitors	In vitro data suggests inhibition of betahistine metabolism, leading to a potential increase in plasma concentration. Caution is formally recommended for concomitant use.
Pharmacodynamic (PD) Interaction	Antihistamines (H1 Antagonists)	Anticipated risk of mutual attenuation of effect of both drugs due to opposing actions on histamine receptors.

The potential for pharmacokinetic change is documented with Monoamine Oxidase Inhibitors (MAOIs). These agents may inhibit the breakdown of betahistine, based on laboratory data, resulting in increased systemic exposure. Co-administration with Antihistamines is anticipated to reduce the effect of both substances. Regarding food, its intake is documented to alter the rate of absorption, causing a lower peak concentration, but the total amount of betahistine absorbed into the bloodstream remains similar. The overall regulatory structure emphasizes caution regarding these two primary drug classes.

The mechanism of action of Вестинорм (Betahistine) centers on its ability to modulate the body's histamine receptor systems ( H1 and H3), which are central to specific signaling dynamics within the neurosensory system.

Modulation of Histamine Receptor Systems

Вестинорм primarily functions as a weak H1 receptor agonist and a high-affinity H3 receptor antagonist. This dual interaction alters the release and activity of the neurotransmitter histamine, engaging mechanisms that modulate dysregulated nerve processes. This modification of early molecular steps initiates the overall mechanistic cascade.

Central Vestibular Pathway Adjustment

By blocking presynaptic H3 receptors, the drug may increase the release of endogenous histamine within the brain, particularly in the vestibular nuclei. This mechanism is associated with an adjustment of pathway activity within targeted neural structures and alters the rate of signaling observed in the vestibular system.

Influence on Inner Ear Microcirculation

The drug's weak H1 agonism is also associated with a downstream physiological effect involving vasodilation (widening of blood vessels) in the microcirculation of the inner ear. This mechanism contributes to a more regulated physiological state by promoting increased microvascular flow to the cochlea and labyrinth and modifies the effects of local mediator activity.

How to Use Вестинорм (Betahistine)

The usage of Вестинорм, which contains the active ingredient betahistine dihydrochloride, is based on pharmacological guidelines for the treatment of vestibular symptoms. The medicine is intended for oral administration in the form of tablets.

---

Dosing and Administration Schedule

Administration Property	Guideline
Daily Dose Range	The usual adult daily dose is between 24 mg and 48 mg of betahistine dihydrochloride.
Starting Dose	Typically begins at 8 mg to 16 mg per individual administration.
Frequency	The total daily dose is administered in divided doses, generally two to three times per day (BID or TID).
Food Relation	Tablets should be taken with meals or immediately after food.
Duration	Treatment is typically long-term, often continuing for several months, as the onset of effect may be delayed.

---

Procedural Instructions and Special Populations

The dosage should be individually adapted based on the patient's response over time. If a dose is forgotten, the instruction is to skip the missed dose and take the next dose at the scheduled time; a double dose should not be taken to compensate.

General guidelines address use in specific populations. For older adults (geriatric patients) and those with hepatic or renal impairment, no specific dose adjustment is typically required based on available data. However, the medication is not recommended for use in children and adolescents under the age of 18, due to a lack of sufficient safety and efficacy data.

Research evidence / Overview of Studies for Вестинорм

Evidence for Use in Ménière's Syndrome

Research for the active ingredient in Вестинорм, betahistine, has been conducted in studies exploring Ménière's syndrome, a condition characterized by fluctuating or episodic manifestations of severe spinning sensations, hearing loss, and ringing in the ears. These studies primarily include short-term and intermediate-term Randomized Controlled Trials (RCTs), where patient groups receiving the compound were compared to groups receiving an inactive substance (placebo).

Research examined outcomes related to physical discomfort and episodic or acute changes in symptoms, monitoring the frequency and severity of vertigo attacks. Findings describe patterns observed in the studies that were not consistent across all high-level reviews. Evidence quality varies across studies, with findings reported as inconsistent across systematic reviews.

Research on Peripheral Vestibular Vertigo

Beyond Ménière's syndrome, research has explored the medicine's role in the study of symptoms related to vestibular vertigo, which includes spinning sensations arising from the inner ear due to other causes. Evidence for this research focus often comes from pooled analyses and older trials that included a broader range of patients with peripheral vestibular symptoms. Some data indicated a pattern where the odds of a favorable clinical outcome were higher in treatment groups compared to placebo; however, results apply only to the populations studied.

Research Consistency and Areas of Uncertainty

The certainty of the evidence supporting the studied outcomes is often categorized as Low to Moderate by major systematic reviews. The primary uncertainty noted by researchers is linked to the natural history of conditions characterized by fluctuating or episodic manifestations, which complicates the ability of research to definitively distinguish observed symptom changes from natural symptom variation. Additionally, long-term outcomes are not fully established, as information on the maintenance of observed symptom patterns requires observation over many months or years.

Key Studies & References Public Assessment Reports of the Medicines Evaluation Board in the Netherlands: Betabare 24 mg tablets (Reflecting regulatory/marketing authorization data)

Common questions about Вестинорм (FAQ)

---

Q: How long does it typically take to see or feel the effects of Вестинорм?

Improvement may not begin to become apparent until approximately two weeks after starting treatment. Official information indicates that the optimal result is often achieved after several months of continuous treatment.

Q: Is Вестинорм intended for short-term or long-term management?

According to official guidance, treatment with this medicine is typically a long-term commitment. It is common for the prescribed course of therapy to continue for several months, particularly since the full effects may take time to develop.

Q: Does Вестинорм help to reduce the frequency or only the severity of vertigo attacks?

Research evidence has examined outcomes related to both the frequency and the severity of vertigo attacks in patients treated with the medicine. Findings from these studies indicate patterns of improvement in both aspects of the condition's symptoms.

Q: Is drowsiness a known side effect of Вестинорм, unlike some other vertigo medicines?

While the medicine is generally considered to have a negligible effect on the central nervous system, official documents list drowsiness as an occasional side effect. However, the most commonly reported nervous system reaction is headache.

Q: Can women who are pregnant use Вестинорм?

Due to a lack of adequate data regarding its use in pregnant women, official prescribing information advises that the medicine is generally preferred to be avoided during pregnancy. Use is reserved for cases where a healthcare professional considers the benefit clearly outweighs the potential risk.

Q: What information is available about using Вестинорм while breastfeeding?

It is not currently known whether the active substance in the medicine is excreted into human breast milk. The decision regarding use while breastfeeding requires consideration by a healthcare professional, weighing the potential benefit to the mother against the potential risk to the child.

Q: Are there any known serious but rare side effects of Вестинорм?

Serious reactions reported since the medicine was marketed include severe hypersensitivity reactions, such as swelling of the face, lips, tongue, or neck, known as angioedema. The frequency of these potentially serious events cannot be reliably estimated from currently available data.

Q: Does taking Вестинорм with food change how it works?

Official prescribing information recommends taking the medicine with meals primarily to help reduce the possibility of stomach issues, which are a common side effect. Although food may slow down the rate at which the active substance is absorbed into the bloodstream, the total amount of the drug absorbed remains similar.

Q: Is it true that people with asthma should use Вестинорм with caution?

Yes, regulatory documents advise caution when the medicine is used in patients with bronchial asthma. This is because there is a possibility that clinical intolerance or bronchospasm (difficulty breathing) may occur. The regulatory profile indicates that careful monitoring may be advised during treatment for this patient group.

Q: What does it mean that Вестинорм is a "histamine analogue"?

Official patient information classifies the medicine as a histamine analogue. This means that the active substance, betahistine, is a compound that is chemically similar to the naturally occurring substance histamine found in the body.

Q: Can Вестинорм help with general dizziness that is not related to the inner ear?

The medicine is specifically indicated for managing symptoms related to inner ear disorders, such as Ménière's syndrome. Regulatory documents specify that it is not the appropriate treatment for dizziness that is related to a disease of the central nervous system.

Q: Is Вестинорм a cure for Meniere's disease symptoms?

According to official patient information, the medicine is intended to help control the symptoms associated with Ménière's syndrome. However, like many other treatments, it does not cure the underlying condition itself.

Q: Is there research showing the long-term effectiveness of Вестинорм?

Scientific reviews of the evidence note that long-term outcomes for maintaining symptom control are not fully established. The certainty of the evidence regarding the long-term patterns of symptom changes is often categorized as low to moderate by researchers.

Q: Why is it said that Вестинорм may improve blood flow to the inner ear?

The medicine's action is associated with promoting increased microvascular flow in the inner ear. This physiological effect involves the widening of very small blood vessels (vasodilation) in the cochlea and labyrinth structures.

Q: Does Вестинорм help with the feeling of ear pressure or fullness?

The medicine is indicated for managing the symptoms of Ménière's syndrome, a condition characterized by vertigo, ringing in the ears (tinnitus), and hearing loss. Ear pressure or fullness is a commonly recognized symptom associated with this syndrome.

Q: What happens if I forget to take a dose of Вестинорм?

The product information states that if a dose is forgotten, the next dose is taken at the regularly scheduled time. Compensating for a forgotten dose by taking a double dose is described as inappropriate.

Q: Does Вестинорм interact with medications for depression, such as MAO inhibitors?

The medicine has a documented interaction with a class of drugs called Monoamine Oxidase Inhibitors (MAOIs), which are sometimes used to treat depression. Official prescribing information formally notes the need for caution if these drugs are taken together.

Q: Can I drink alcohol while I am using Вестинорм?

Official patient information, based on current regulatory data, indicates that the use of this medicine is generally compatible with drinking alcohol.

Q: Is it safe to take motion sickness medication with Вестинорм?

Many commonly used motion sickness medicines belong to the class of antihistamines. Regulatory documents note that taking the two together may cause a mutual reduction in the effects of both drugs due to their opposing actions on histamine receptors.

Q: Is Вестинорм the same as other medications prescribed for vertigo, like cinnarizine?

The medicine is classified as a histamine analogue and acts as an antivertigo preparation. Other medicines prescribed for vertigo, such as cinnarizine, belong to different pharmacological classes, like calcium channel blockers.

Q: Can Вестинорм be used for all types of positional vertigo?

Regulatory documents specify that the medicine is not considered the appropriate treatment for certain specific forms of dizziness. This includes attacks of benign positional vertigo, which may require different management strategies.

Q: What is the status of Вестинорм's regulatory approval in different countries, such as the US?

The active ingredient is widely recognized and approved in Europe and other global markets. However, the U.S. Food and Drug Administration (FDA) has currently not approved it for use in the United States.

Q: Does my diagnosis have to be Ménière's syndrome to be prescribed Вестинорм?

The primary therapeutic indication is the management of symptoms associated with Ménière's syndrome. However, the medicine has also been studied in relation to other conditions involving recurrent peripheral vestibular vertigo.

Q: Do the side effects of Вестинорм usually go away over time?

Mild gastric complaints, such as nausea or abdominal discomfort, are the most common side effects reported. These can often be addressed by taking the medicine during meals or by consulting a professional about adjusting the dosage, according to patient information.

Q: Why is a history of allergic skin conditions sometimes noted as a precaution with Вестинорм?

Regulatory documents advise caution because of the possibility of the medicine aggravating pre-existing allergic skin conditions. This includes conditions such as hives (urticaria), rashes, and allergic rhinitis.

Q: Does Вестинорм carry a risk of long-term dependence or addiction?

Official patient information, provided by regulatory authorities, indicates that there is no evidence suggesting the active ingredient has addictive properties. Therefore, it does not carry a risk of long-term dependence.

Q: What are the possible signs of an allergic reaction to Вестинорм?

Signs of a potentially serious allergic reaction reported include swelling of the face, lips, tongue, or neck (known as angioedema), or skin reactions such as severe itching (pruritus), rash, or hives (urticaria).

How to Store and Dispose of VestiNORM?

VestiNORM tablets must be stored at or below 25 C and must be protected from light and moisture. Storage should be in the original container and kept away from both excess heat and dampness. The official labeling specifies that the medicine must be stored in a locked cupboard and kept out of the sight and reach of children.

Storage Restriction	Requirement as per Regulatory Labeling
Temperature	Store at or below 25 C
Protection	Protect from light and moisture
Location	Keep out of the sight and reach of children

Disposal: Unused or expired VestiNORM must not be disposed of via household waste or wastewater. The product must be returned to a pharmacist or disposed of according to local pharmaceutical waste regulations to protect the environment.